Global Pain Treatment Pipeline Discussed by GBI Research in Topical Report Published at

08 May 2015 • by Natalie Aster

LONDON – The active pipeline of the world pain treatment market is inhabited with 796 products across all development stages, which demonstrates an extremely diverse range of molecular targets. There are 122 first-in-class  programmes in active development that have been identified, accounting for just over 13.5% of the pipeline and acting on 65 first-in-class molecular targets, which signifies a high level of innovation.  Meantime, the pain therapeutics market has been mainly characterised by incremental innovation of products over the last ten years, as the majority of market segments keep on being dominated by long-established active pharmaceutical ingredients (APIs) and the concurrent mechanisms of action (MoA).

In the worldwide pain treatment market, opioid drugs continue to be used for moderate and severe pain, and they are increasingly being reformulated to provide abuse resistance; whilst non-steroidal anti-inflammatory drugs effectively treat mild pain. However, there are still significant unmet needs left, as chronic pain and some neuropathic pains do not respond pproperly to current therapies, which are not adequate for the treatment of associated hypersensitisation and do not align to the underlying molecular pathophysiological profile.

In the past 8 years, pain therapy deals have been primarily active, approximating 261 licensing deals and 112 co-development deals.

Topical study “Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research offers a comprehensive analysis of the licensing of products in tandem with the co-development active deals in the world pain treatment market. It also presents details about the growing investment opportunities for drug manufacturers.

It gives a brief review of pain, including the different pain subtypes, pathophysiology, and overview of pharmacotherapy and treatment guidelines. The report examines the dynamic landscape of molecular targets between market and pipeline along with main points of innovation in the pipeline. It analyses the pipeline for first-in-class therapies, based on development stage, molecular target and molecule type. The study identifies and assesses first-in-class molecular targets focusing mainly on early-stage programmes, besides offering literature reviews on new molecular targets. An assessment of the co-development and licensing deals for pain therapies as well as benchmarking of deals involving first-in-class vs. non-first-in-class-products.

Report Details:

Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation
Published: January, 2015
Pages: 72
Price: US$ 3,500.00

More reports by the publisher can be found at GBI Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970